Latest Als (ASX:ALQ) News

ALS Limited has completed a significant institutional placement, issuing over 20.9 million shares at A$16.70 each, bolstering its capital base without the need for full disclosure under the Corporations Act.

ALS Limited has successfully completed a $350 million institutional placement, issuing 21 million new shares to fund key laboratory upgrades and maintain financial flexibility. The company also launched a $40 million share purchase plan to further support its growth ambitions.

ALS Limited has announced a fully underwritten A$350 million equity placement to fund major upgrades to its global laboratory network and support future growth initiatives, aiming for mid single-digit EPS accretion by FY25 pro forma.

ALS Limited has announced an ordinary dividend of AUD 0.197 per share for the half-year ending March 2025, payable in July with flexible currency options for shareholders worldwide.

ALS Limited delivered a robust FY25 performance with 16% revenue growth to $3 billion and underlying EBIT rising 4.7% to $515 million, driven by strong organic growth and strategic acquisitions. The company is advancing its Nuvisan integration ahead of schedule and has unveiled a $230 million investment plan to expand key laboratories, positioning itself for sustained growth amid market uncertainties.

ALS Limited reported a robust FY25 with $3 billion revenue driven by Life Sciences growth and resilient Commodities, announcing a $350 million equity raise to fund strategic expansion.

ALS Limited reported a 16% revenue increase to nearly $3 billion in FY2025, driven by acquisitions and organic growth, while underlying net profit after tax dipped slightly. The company announced a $350 million equity raise to fund expansion and sustainability initiatives.